Rabies vaccine administration is the most effective method to prevent the occurrence of rabies disease. However, administration of rabies vaccine without adjuvant always shows low efficiency. As a member of superantigen, staphylococcal enterotoxin C2 (SEC2) non-specifically activates T-cells at extremely low concentration. It enlightens us that SEC2 may be used as an adjuvant. We carried out the experiment that the mice received twice immunization with rabies vaccine in the presence or absence of SEC2 at 1-week interval. Serum and splenocytes from immunized mice were collected to measure the level of rabies-specific-IgG and the cell that secretes IFN-γ or IL-4. The promotion of antigen-specific splenocytes proliferation was also detected. Besides, a challenge test was performed to evaluate the protective efficiency of SEC2. It was shown that mice immunized with vaccine combined with SEC2 generated more specific anti-rabies-antibodies. The results for production of IFN-γ and IL-4, as well as the proliferation of splenocytes from immunized mice indicated SEC2 promoted the specific immune responses induced by rabies vaccine. Moreover, immunization of mice with vaccine combined with SEC2 provided efficient protection against the lethal rabies exposure. Taken together, our findings indicated that SEC2 can be served as an adjuvant for rabies vaccines.
INTRODUCTION
Rabies is one of the most lethal infectious diseases caused by rabies virus. With nearly 100% mortality rate (Johnson, Cunningham and Fooks 2010) , rabies annually kills more than 55 000 people worldwide (WHO 2005) and most of those sufferers came from developing countries (Meng et al. 2010) . So far, rabies vaccine administration is still the most effective method to prevent the occurrence of rabies disease after post-exposure to rabies virus (Starodubova et al. 2015) . However, most of the commercial rabies vaccine showed low immunogenicity currently and occasionally led to the failure of protection (Hu, Liu and Zhu 2013) . Although a combined application with appropriate adjuvant is a feasible method to improve the efficacy of vaccine, chemical adjuvants such as aluminium hydroxide is not permitted to be added into commercial products of rabies vaccine for human usage in China. As a result, a low protection or vaccination failure may occur for human usage in China. Whereas current solution is to repeatedly immunize for at least three times to ensure the protection efficiency of rabies vaccine, their exploration of new types of safe adjuvant that improve the immunogenicity and protection of rabies vaccine is urgently needed.
Staphylococcal enterotoxin C2 (SEC2) belongs to the family of superantigens (SAgs) which are secreted by Staphylococcus aureus. SAgs can directly activate T-cells or B-cells without the presence of antigen-presenting cells (APC) (Omoe et al. 2005) . About 2%-20% human T-cells can be activated by SAgs even at a very low concentration (<10 ng/ml) (Kum et al. 2001 ). Our previous studies showed that SEC2 can significantly induce the T-cells activation (Xu et al. 2011; Liu et al. 2012 Liu et al. , 2013 Zhou et al. 2013; Zhang et al. 2016a) . Furthermore, it has been documented that some kinds of SAgs such as staphylococcal enterotoxin A and B (SEA, SEB) which are homologous to SEC2 can activate downstream pathways of Toll-like receptors (TLRs), the key receptors linking innate immunity and adaptive immunity (Ertl 2009; Kasturi et al. 2011; Zhang et al. 2013) . TLRs are also important in activation of innate immune response elicited by virus. Additionally, some new kinds of adjuvants work as ligands of a kind of TLRs (Su et al. , 2015 Liu et al. 2016b; Zhang et al. 2016c) . Taking all these together, we hypothesize that SEC2 could also be used as a potential adjuvant of rabies vaccine.
In present study, we evaluated the efficiency of SEC2 as adjuvant for rabies vaccine. Our study indicated that SEC2 can efficiently promote the immunogenicity and protection rate of rabies vaccine in mice, highlighting the usefulness of SEC2 as a vaccine adjuvant against rabies virus infection.
MATERIAL AND METHODS

Animals
Female BALB/c mice (4-6 weeks old) were purchased from Beijing Vital River Laboratory Animal Technology Co. Ltd (Beijing, China) and maintained under specific pathogen-free conditions. Feed and water were supplied ad libitum. All animals were treated according to the regulations for the administration of affairs concerning experimental animals by the government of China, and this study was approved by the Liaoning Provincial Laboratory Animal Public Service Center.
Chemicals and reagents
Rabies vaccine (Vero cells were inoculated with rabies virus fixed strain ctn-1v. After culture, the virus were harvested, inactivated, concentrated and purified to obtain the rabies vaccine. The efficacy of rabies vaccine is above 2.5 IU each dose in 0.5 ml) was generous supplied by Chengda Biotechnology Co. Ltd (Shenyang, China). SEC2 is prepared and preserved by our laboratory (Xu et al. 2011) , and the endotoxin was removed by ToxinEraser Endotoxin Removal Kit (Genscript, China). Concanavalin A (Con A) was purchased from Sigma Chemical Co., Ltd (Saint Louis, USA). IFN-γ and IL-4 enzyme-linked immune spot assay (ELISPOT) kit were purchased from eBioscience (Waltham, USA). Goat anti-mouse IgG peroxidase conjugate, Goat anti-mouse IgG1 peroxidase conjugate, Goat anti-mouse IgG2a peroxidase conjugate and all other regents related to enzyme-linked immunosorbent assay (ELISA) were purchased from Bethyl Laboratories, Inc. (Montgomery, USA). Cell Titer 96 Aqueous One Solution Cell Proliferation assay (MTS) was purchased from Promega (Madison, USA). RNAiso kit for total RNA extraction, PrimeScript RT Master Mix (Perfect Real Time) kit for RNA reverse transcription and SYBR Premix Ex Taq Kit for real-time PCR assay were purchased from Takara (Dalian, China). RPMI-1640 and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific (Hyclone, Waltham, MA, USA).
Immunization
Thirty-Six female BALB/c mice were randomly divided into four groups with nine mice per group. The mice were intraperitoneally injected (i.p.) twice at 1-week intervals with phosphatebuffered saline (PBS), PBS containing SEC2 (30 μg), rabies vaccine (diluted to 125 times with PBS and the final dose is 0.02 IU) or rabies vaccine (diluted to 125 times with PBS and the final dose is 0.02 IU) containing SEC2 (10, 30, 100 μg). Blood samples were collected from orbital venous sinus three times (before primary immunization: day 0, 1 week after the primary immunization: day 7, and 1 week after the boost immunization: day 14). The serum was separated by centrifugation (4000 rpm, 20 min) and kept at -80
• C until use. Serum (50 μl) was collected from each mice every time. Then, the splenocytes were harvested at 1 week after the booster immunization for splenocytes proliferation and ELISPOT assay.
Measurement of rabies-specific IgG and subclass
An indirect ELISA was conducted to detect serum rabies-specific IgG according to the manufacture's instruction. Briefly, microtiter plate was coated with 100 μl rabies vaccine (diluted to 30 times with ELISA coating buffer) for overnight at 4
• C. After washing three times with ELISA wash buffer, the wells were blocked with ELISA blocking buffer and incubated at 37
• C for 1 h. After washing with ELISA wash buffer, 100 μl of serum samples was added to each well in a serially double dilution from 1:100 to 1:12 800 (1:100 dilution for IgG1 and IgG2a detection only) and incubated at 37
• C for another 1 h. After washed five times, goat antimouse IgG (or IgG1/IgG2a) peroxidase conjugate (1:10 000) was added to each well and incubated at 37
• C for 1 h. Then, plate was washed again before 50 μl TMB one component substrate had been added to each well and incubated at 37
• C for 15 min.
The reaction was stopped by adding 50 μl ELISA stop solution to each well. The optical density of the plate was read by an automatic microplate reader at 450 nm. Values above the cut-off background level (mean value of sera from unimmunized mice multiplied by a factor of 2.1) were considered positive. Titers were depicted as reciprocal end-dilutions. The experiment was repeated three times.
Splenocytes proliferation assay
Mice spleen was collected 1 week after the last immunization, and homogeneous splenocytes suspension was obtained by passing through a fine steel mesh under aseptic conditions. The erythrocytes were lysed with 0.83% NH 4 Cl in 0.01 M TrisHCl (pH 7.2). After centrifugation (300× g at 4 • C, for 5 min), the pelleted cells were collected and washed twice in RPMI-1640, then resuspended in complete medium (RPMI-1640 supplied with 10% FBS). Cell numbers were counted with a haemocytometer. To check splenocytes proliferation, splenocytes were seeded into a 96-well microtiter plate at 2.0 × 10 6 cells/ml in 50 μl complete medium. Then, 50 μl Con A (positive control, 5 μg/ml final concentration), rabies vaccine (diluted to 10 times as final concentration) or medium only (negative control) were added to each well respectively giving a final volume of 100 μl per well. The wells with 100 μl medium only were settled as a blank. The plates were incubated at 37
• C in a humid atmosphere with 5% Forward:5 -CCATATCCACGGATGCGACA-3 Reverse:5 -AAGCACCTTGGAAGCCCTAC-3 CO 2 for 2 days. All the treatments were settled in triplicate wells. The cell proliferation was evaluated using MTS. Briefly, 20 μl of MTS were added to each well 4 h before the end of incubation. Thereafter, the absorbance was evaluated in a microplate reader at 490 nm. The stimulation index (SI) was calculated based on the formula: SI = (the absorbance value for treatment well -the absorbance value for blank well)/(the absorbance value for negative control well -the absorbance value for blank well). The experiment was repeated three times.
Animal experiment
To evaluate the effect of SEC2 on mice protection induced by rabies vaccine, mice (n = 18/group) were i.p. injected with PBS, SEC2, vaccine or vaccine combined with SEC2 on day 0 and day 7. The mice were challenged 1 week after the last immunization by intramuscular injection of 31.62 × LD 50 of rabies Challenge virus strain (provided by Chengda Biotechnology Co. Ltd) in a 100-μl volume. The survival of mice was observed for 14 days. The experiment was repeated three times.
Quantitative real-time PCR of IFN-γ and IL-4
Treated cells were acquired by the method mentioned in section 'Splenocytes proliferation assay'. To determine the expression of target genes (IFN-γ and IL-4), the total RNA from each treated sample was isolated by RNAiso kit according to the manufacturer's protocol. Then, 0.5 μg of total RNA from each sample was reverse transcribed to cDNA. Quantitative real-time PCR was performed in triplicates using the SYBR Premix Ex Taq Kit with ABI Prism 7000. Amplification was carried out in a total volume of 25 μl containing 1 μl of cDNA template, 1 μl of forward primer, 1 μl of reverse primer, 9 μl of nuclease-free water, 0.5 μl of ROX, and 12.5 μl of SYBR premix Taq (2× 
IFN-γ and IL-4 ELISPOT
ELISPOT kits (eBioscience, USA) were used to measure the IFN-γ -or IL-4-producing-splenocytes onsite. Briefly, 100 μl splenocytes (cells were harvest as described in section 'Splenocytes proliferation assay') at a density of 1 × 10 6 cell/ml were added to precoated 96-well plate with rabies vaccine (diluted to 10 times as final concentration) and incubated for 24 h in a humidified incubator at 37
• C with 5% CO 2 . Cell treated with 10 μl PMA was settled as positive control, and cell without any treatment was settled as negative control. Besides, the experimental groups include PBS group, SEC2 group, vaccine group and vaccine combined with SEC2 group used rabies vaccine as stimulant. Following the instruction of the ELISPOT kits, cells used in positive and negative control groups were derived from blank mouse (immunized with PBS only). Plates were then washed and processed according to the manufacturer's protocol. The experiment was repeated three times.
Statistical analysis
Data were expressed as means ± standard deviations (SD). Twosided Student's t-test for unpaired was used to compare the parameters between groups using SPSS 19.0. The data of challenge test were analyzed using a Logrank test through GraphPad Prism 6. P values < 0.05 were considered to be statistically significant, and P values < 0.01 were considered to be extremely statistically significant.
RESULTS
SEC2 enhanced rabies-specific IgG level in immunized mice
There was no obvious toxicity when the mice were treated with SEC2, including weight loss, fever and other symptoms. It was shown that SEC2 treatment only was irrelevant with rabiesspecific IgG (Fig. 1A) . Rabies vaccine elicited significant rabiesspecific IgG responses on day 7 and day 14. Furthermore, vaccine combined with 30 or 100 μg SEC2 per mouse induced rabiesspecific IgG in a significantly higher level than vaccine only (30 μg: P < 0.01 for day 7, P < 0.01 for day 14; 100 μg: P < 0.05 for day 7, P < 0.01 for day 14). However, vaccine combined with 10 μg SEC2 per mouse showed no significant difference compared with vaccine only in day 7. Since there was also no significant difference between vaccine combined with 30 μg SEC2 and vaccine with 100 μg SEC2, we chose 30 μg as the optimal dose in our following experiments. In addition, the results of both IgG1 and IgG2a subclass exhibited similar tendency as showed in Fig. 1B and C (P < 0.01).
SEC2 increased the survival rate of immunized mice in challenge test
To evaluate whether SEC2 augment the protective efficacy of rabies vaccine against rabies virus challenge, mice immunized with different components were challenged with a lethal dose of Challenge virus strain at 1 week after the boost immunization. After virus infection, mice manifested severe neurological signs and died in next days. It was shown that all mice immunized with either PBS or SEC2 alone died in the end of challenge (Fig. 2) . Nine of eighteen mice were protected in the group immunized with vaccine and SEC2 (50.0% protection rate). In contrast, only three mice were survival in vaccine only group (16.7% protection rate).
SEC2 stimulated proliferation of splenocytes from immunized mice
Effects of SEC2 combined with rabies vaccine stimulated splenocytes proliferation in the immunized mice were shown in Fig. 3 , no significant difference was observed in response to both Mice were immunized with PBS, SEC2, vaccine or vaccine combined with SEC2 at a dose of 10, 30 or 100 μg each mouse with 1-week intervals (day 0, day 7). Blood samples were collected at day 0, day 7 and day 14. Results are expressed as the mean value ± SD (n = 9). ' * ' represents P < 0.05, ' * * ' represents P < 0.01.
The experiment was repeated three times.
Figure 2.
Challenge test in Balb/c mice. Animals from each groups (n = 18) were challenged with 31.62 LD50 of CVS followed immunized with PBS, SEC2, vaccine or vaccine combined with SEC2 at a dose of 30 μg each mouse with 1-week intervals (day 0, day 7). The survival of mice was observed for 2 weeks. The data were analyzed using a Logrank test. ' * ' represents P < 0.05, ' * * ' represents P < 0.01. The experiment was repeated three times. . Splenocytes were isolated and collected from immunized mice in each group 1 week after boost immunization and incubation at 37
• C for 48 h. Con A and rabies vaccine were used in splenocytes proliferation assay as non-specific or specific stimulation. Results are expressed as the mean value ± SD (n = 3). ' * ' represents P < 0.05, ' * * ' represents P < 0.01. The experiment was repeated three times.
non-specific and specific stimulation by vaccine only group or SEC2 only group compare with PBS group. However, vaccine combined with SEC2 showed significantly enhanced stimulations in both non-specific and specific proliferations compared with vaccine only (P < 0.05 for non-specific, P < 0.01 for specific).
SEC2 induced more IFN-γ or IL-4 producing cell
To determine SEC2 and/or vaccine induced cytokines production from Th1 or Th2 cells, splenocytes from immunized mice were isolated 1 week after the boost immunization. The cells that secrete IFN-γ or IL-4 were measured by ELISPOT. The results were shown in Fig. 4A and B. As a control, PBS did not induce obvious cell which produce IFN-γ or IL-4 in our experiment. Although a few cytokines-producing splenocytes were detected from SEC2 alone treated mice, there was no Figure 4 . The cytokines producing cell were measured. Mice were immunized with PBS, SEC2, vaccine or vaccine combined with SEC2 with 1-week intervals (day 0, day 7). Splenocytes were isolated and collected from immunized mice in each group 1 week after boost immunization. The cells were plated at a density of 5 × 10 6 cells/ml. Cytokine production by splenocytes in response to rabies vaccine stimulation was measured by ELISPOT assay (A, B) . The mRNA of cytokines was measured by qPCR (C). Results are expressed as the mean value ± SD (n = 3). ' * ' represents P < 0.05, ' * * ' represents P < 0.01. The experiment was repeated three times.
statistical significance between SEC2 treatment and PBS treatment (P > 0.05). Both vaccine treatment and vaccine combined with SEC2 treatment induced large number of IFN-γ -producing cells and IL-4-producing cells. However, vaccine combined with SEC2 induced more IFN-γ -producing cells and IL-4-producing cells than the vaccine alone (P < 0.05 for IFN-γ -producing cells, P < 0.01 for IL-4-producing cells).
SEC2 increased mRNA transcription of IFN-γ and IL-4 by splenocytes from immunized mice
To investigate the effects of SEC2 on cytokine in mRNA transcription, total RNA was isolated from splenocytes on day14 and quantified by real-time PCR. The result was shown in Fig. 4C . SEC2 alone did not induce any obvious change of IFN-γ and IL-4 transcription. Meanwhile, vaccine induced the obvious change of IFN-γ and IL-4 transcription. However, vaccine combined with SEC2 induced a significant increase of IFN-γ and IL-4 transcription compare with vaccine alone (P < 0.01).
DISCUSSION
Rabies is still a severe public health problem for killing more than 55 000 people every year worldwide. As far as current technology, rabies vaccine is the only way we can choose to prevent the disease. However, commercial rabies vaccines without adjuvant usually show low efficiency in clinical usage and need to be administered repeatedly (Zhang et al. 2016b) . Aluminum hydroxide as a licensed adjuvant has been used in some commercial vaccine. However, it cannot induce enough antibody and cytokines as we expected (Brewer et al. 1999; Lindblad 2004) . So, novel adjuvant especially for rabies vaccine is urgently needed. As a kind of SAgs, SEC2 secreted by Staphylococcus aureus could bind with MHC-II molecules and TCR molecule directly and activates T-cells even at extremely low concentration. It is reported that other kinds of staphylococcal enterotoxins with high homologous to SEC2 such as SEA and SEB could upregulate the expression of MyD88 and TRAF-6 which were the key signaling molecules in Toll-like receptors (TLRs) signaling pathways in both T-cells and APC (Kissner et al. 2010 (Kissner et al. , 2011a . As a result, staphylococcal enterotoxin promotes T-cells polarization and activates TLRs signaling pathways in APC (Mandron et al. 2006; Liu et al. 2007) . Furthermore, TLRs are important in activation of innate immune response elicited by virus. So, we hypothesize that SEC2 has potential as an adjuvant for rabies vaccine.
In this study, we examine the potential of SEC2 as rabies vaccine adjuvant. First, rabies-specific antibodies were detected, as antibody is one of the most important indicators in infection. We detected immunoglobulin G because it has the largest amount in all five types of immunoglobulins in the body. As far as we know, the latent period for rabies virus can be as short as 1 week (Dietzschold, Schnell and Koprowski 2005) . Once exposed to rabies virus, specific immunoglobulin is needed in urgency for the patient. So we chose day 0, day 7 and day 14 as target time in this study. We found that SEC2 alone cannot induce the production of rabies-specific IgG. However, mice received vaccine combined with SEC2 as an adjuvant had significantly higher rabies-specific IgG titer than vaccine alone on day 7 and day 14. It suggests that SEC2 could provide enhanced early protection of rabies vaccine.
Different infections induce distinct types of immune cells responses. Th1 cells are induced by intracellular infections and accompanied by the production of cytokines such as TNF-α and IFN-γ , leading to an enhanced production of IgG2a, IgG2b and IgG3 in mice. Th2 cell is required for protection against viral infection with the production of cytokines IL-4, IL-5 as representation, leading to an enhanced production of IgG1 (Delprete et al. 1991; Livingston et al. 1994; Constant and Bottomly 1997) . IgG2a has been shown to be more effective than IgG1 in the resistance of rabies virus infection (Gomme et al. 2010; Yendo et al. 2016) because it can initiate a complement pathway, bind to various Fc receptors and stimulate antibody-dependent cell-mediated cytotoxicity against virus infection (Liu et al. 2016b) . Our results indicated that rabies vaccine combined with SEC2 significant increased the production of both IgG1 and IgG2a than vaccine alone, especially at day14, which means that SEC2 can enhance both Th1 and Th2 immune cells responses in the presence of rabies vaccine.
Cytokines are also necessary for immune responses to clear virus infection. As we know, IFN-γ is mainly secreted by Th1 cell while IL-4 is mainly secreted by Th2 cell. (Nair et al. 2011; Sant and McMichael 2012; Swain, McKinstry and Strutt 2012) . In this study, the result from ELISPOT assay (Fig. 4) showed that SEC2 combined with rabies vaccine group could induce more IFN-γ -producing cell and IL-4-producing cell than other groups. This result further indicated that vaccine combined with SEC2 improved both Th1 and Th2 immune cells responses compared with vaccine alone or SEC2 alone. The results of qRT-PCR also confirm that these two cytokines have similar changes in transcription level.
The effectiveness of vaccine combined with SEC2 on immunized mice splenocytes is also measured through MTS assay and demonstrated as SI (Fig. 3) . Vaccine combined with SEC2 has a significant higher SI compared with vaccine alone under conditions of both non-specific and specific stimulation, indicating a notable synergy in the enhancement of the immunogenicity of the vaccine. However, no significant difference was observed between the vaccine alone group and the PBS group in both nonspecific and specific stimulation. These results were similar with Hu's report, wherein rabies vaccine alone could not induce sufficient cellular immune response without the assistance of potent adjuvants (Hu, Liu and Zhu 2013) .
It is vital for rabies vaccine to induce fast and robust immune responses to eliminate the invasive virus before virus entering the nervous system (Liu et al. 2016a ). According to our data (Fig. 2) , we found that rabies vaccine combined with SEC2 protected mice against high dose of rabies virus infection with a higher survival rate compare with rabies vaccine alone. This result further confirms the usefulness of SEC2 as an effective adjuvant to the rabies vaccine.
In summary, our works indicated that vaccine combined with SEC2 provided an enhanced protection against rabies virus infection in mice, which might be mediated by eliciting an increased level of rabies-specific IgG and Th1-type and Th2-type immune response. Our study highlighted the potential of SEC2 as a novel adjuvant to the rabies vaccine.
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